Patents by Inventor Christopher D. HEIN

Christopher D. HEIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF
    Publication number: 20220402866
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 8, 2021
    Publication date: December 22, 2022
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
    Patent number: 11208377
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: December 28, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • EPagonists as therapeutic compounds
    Patent number: 10407382
    Abstract: Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: September 10, 2019
    Assignee: ALLERGAN, INC.
    Inventors: David W. Old, Christopher D. Hein
  • 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF
    Publication number: 20190047947
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 14, 2019
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS
    Publication number: 20180170858
    Abstract: Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
    Type: Application
    Filed: February 20, 2018
    Publication date: June 21, 2018
    Inventors: David W. Old, Christopher D. Hein
  • EP4 agonists as therapeutic compounds
    Patent number: 9926262
    Abstract: Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: March 27, 2018
    Assignee: ALLERGAN, INC.
    Inventors: David W. Old, Christopher D. Hein
  • NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS
    Publication number: 20170183293
    Abstract: Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
    Type: Application
    Filed: June 5, 2015
    Publication date: June 29, 2017
    Inventors: David W. OLD, Christopher D. HEIN